1. Home
  2. RMCF vs INAB Comparison

RMCF vs INAB Comparison

Compare RMCF & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

HOLD

Current Price

$0.86

Market Cap

14.9M

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.08

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCF
INAB
Founded
1981
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
13.7M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
RMCF
INAB
Price
$0.86
$1.08
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
54.5K
48.8K
Earning Date
06-16-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
34.88
N/A
EPS
N/A
N/A
Revenue
$30,432,352.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$1.06
52 Week High
$2.99
$2.73

Technical Indicators

Market Signals
Indicator
RMCF
INAB
Relative Strength Index (RSI) 31.73 25.47
Support Level $0.84 N/A
Resistance Level $1.19 $1.46
Average True Range (ATR) 0.08 0.06
MACD 0.01 -0.02
Stochastic Oscillator 4.47 3.68

Price Performance

Historical Comparison
RMCF
INAB

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: